Browse the evidence

Patients may benefit from education on proper drug administration, anticipated adverse effects, and nutrition considerations with treatment.

Educating patients on these aspects can improve treatment adherence and outcomes.

Durable LVAD patients treated with GLP-1 RA had a significant weight reduction from 116 kg to 110 kg (p-value < 0.001).

GLP-1 RA may be effective for weight management in LVAD patients.

GLP-1 RA therapy improved HBA1C levels from 6.4 to 5.7 (p-value 0.003) in LVAD patients.

GLP-1 RA may help improve glycemic control in LVAD patients.

Dulaglutide showed consistent reductions in HbA1c (1.1%) and weight (1.2 kg).

Dulaglutide is an effective alternative for glycemic control and weight management in T2DM patients.

Several emerging oral agents have demonstrated promising efficacy, achieving weight loss of ≥10% in clinical trials.

Practitioners may consider these oral agents as effective options for weight management.

Incretin-based anti-obesity medications are gaining interest for their potential role in preconception care.

Healthcare providers should consider the use of incretin-based medications in preconception counseling.

Ninety-day medical complications were significantly reduced in GLP-1 RA users across BMI categories ≥25.

Practitioners may consider GLP-1 RA use to reduce post-operative complications in obese patients.

Two-year surgical complications were lower among GLP-1 RA users in BMI 35 to 39.9 and ≥40 groups.

GLP-1 RA may be beneficial for reducing long-term surgical complications in higher BMI patients.

GLP-1 RA use was associated with significantly reduced risk of revision at 10 years in the 25.0 to 29.9 BMI group.

Consideration of GLP-1 RA may improve long-term surgical outcomes in patients with lower BMI.

Incretin-based therapy reduced all-cause mortality by 18%.

Incretin-based therapies may improve survival rates in overweight or obese individuals.

GLP-1 receptor agonists (GLP-1RAs) may influence skeletal muscle through anti-inflammatory, antioxidant, and mitochondrial-supportive mechanisms.

Practitioners should consider the potential muscle-preserving effects of GLP-1RAs in patients at risk for sarcopenia.

GLP-1RAs have shown muscle-preserving properties in experimental models of aging, sarcopenic obesity, and chronic disease.

GLP-1RAs may be beneficial in preserving muscle in specific populations, such as the elderly or those with chronic diseases.

Obesity leads to inflammation and altered hormone production that can promote cancer development.

Understanding the hormonal and inflammatory changes in obesity can help in developing targeted interventions for cancer prevention.

Semaglutide is the most cost-effective treatment option in the severe obesity patient population and in first-tier cities in China.

In specific urban populations with severe obesity, semaglutide may be a preferred treatment option.

Lifestyle management was the most likely to be cost-effective under the willingness-to-pay threshold.

Lifestyle interventions should be prioritized for cost-effective obesity management.

Semaglutide was associated with a reduction in heavy drinking days by -41.1 percentage points from baseline compared to placebo, which had a reduction of -26.4 percentage points.

Semaglutide may be a viable treatment option for reducing heavy drinking in patients with alcohol use disorder and obesity.

Semaglutide improved heart failure symptoms and physical limitations in participants with obesity-related HFpEF.

Practitioners can consider semaglutide as an effective treatment for improving symptoms in patients with obesity-related HFpEF.

Weight loss in the GLP-1 RA group was directly associated with bone loss at the total hip (TH) and femoral neck (FN).

Weight management strategies may need to consider potential impacts on bone health.

Randomized trials with liraglutide and semaglutide have shown reductions in major adverse cardiovascular events.

These medications may be beneficial for patients at high risk of cardiovascular events.

Semaglutide improved lipid parameters, including reductions in LDL cholesterol and non-HDL cholesterol levels.

Semaglutide may be beneficial for improving lipid profiles in patients with T2DM.

Visceral and ectopic fat accumulation strongly predicts adverse lipid patterns, insulin resistance, and cardiovascular events.

Focus on reducing visceral and ectopic fat to improve lipid profiles and reduce cardiovascular risk.

Lifestyle interventions demonstrate favorable effects on lipid metabolism independent of weight loss.

Encourage patients to adopt lifestyle changes for lipid management, even if weight loss is not achieved.

Roux-en-Y gastric bypass was associated with less gastroesophageal reflux disease (GERD)-related symptoms compared to sleeve gastrectomy.

Surgeons may prefer Roux-en-Y gastric bypass for patients concerned about GERD symptoms.

GLP-1 receptor agonists (GLP-1 RAs) have been presumed to positively influence erectile function.

GLP-1 RAs may be considered in the management of erectile function in diabetic patients.